ills have served biopharma pretty well over the years. Easy to design and cheap to produce, the so-called small-molecule therapies that fit in a capsule have made billions of dollars for their inventors and treated millions of patients in the process.

Now, however, as yesteryear’s swallowable blockbusters go generic, the industry is running into diseases for which pills can find no quarter.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Boston Globe – This is a huge “bait and switch”! I pay for my subscription to the Globe and when I click on the first article in the business section, you tell me you want more money!?! This leaves a really bad taste in my mouth.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine